Key statistics
As of last trade Royalty Pharma PLC (RPD:FRA) traded at 24.73, 5.50% above its 52-week low of 23.44, set on Jul 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.73 |
---|---|
High | 24.73 |
Low | 24.73 |
Bid | 24.70 |
Offer | 25.57 |
Previous close | 24.49 |
Average volume | 2.65k |
---|---|
Shares outstanding | 589.18m |
Free float | 380.86m |
P/E (TTM) | 10.25 |
Market cap | 15.45bn USD |
EPS (TTM) | 2.56 USD |
Annual div (ADY) | 0.7968 EUR |
---|---|
Annual div yield (ADY) | 3.25% |
Div ex-date | Nov 15 2024 |
Div pay-date | Dec 10 2024 |
Data delayed at least 15 minutes, as of Nov 21 2024 07:24 GMT.
More ▼
Announcements
- Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
- Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
- Royalty Pharma Reports Third Quarter 2024 Results
- Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo
- Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
- Royalty Pharma Declares Fourth Quarter 2024 Dividend
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
- Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
- Royalty Pharma Reports Second Quarter 2024 Results
- Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
More ▼